🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden flag Sweden · Delayed Price · Currency is SEK
467.80
-6.40 (-1.35%)
Nov 19, 2026, 5:29 PM CET
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Strategy and the SEK 55bn 2030 target remain unchanged, with multiple launches supporting growth and investment through 2027. Gout programs advance toward mid-2027 filings, while Doptelet U.S. exclusivity ends in July 2027.

Michael Leuchten
Analyst, Jefferies

We have Daniel Rankin and Gerard Tobin, both joining us today to chat through a little bit of what to look forward to into next year, I guess, is the way we are going to focus into it. Some good news this morning that I want to touch on as well. To kick it off, I will hand it over to you for just a couple of introductory remarks, a little bit of background about the recent goings on of SOBI, and then we will go on from there in the fireside chat.

Daniel Rankin
Chief Business Officer, SOBI

I am Daniel Rankin, Chief Business Officer here at SOBI. I have been with the company for nine years. I have a broad portfolio responsible for strategic marketing, as well as BD and M&A, and was behind all of the deals we did in the last nine years.

Gerard Tobin
Head of Investor Relations, SOBI

Gerard Tobin, Head of Investor Relations for SOBI.

Michael Leuchten
Analyst, Jefferies

The first question we typically get asked here is obviously with Guido stepping down going into next year, people often ask us about the continuity of strategy, what could change, and what developments there are on that front. Do you want to talk to us a little bit about how strategy might change going forwards, and then if there is any updates you can provide in and around the potential board hiring and updates we could get there?

Daniel Rankin
Chief Business Officer, SOBI

Yeah. I think first of all, it's a CEO who's very much leaving at a good part. He's leaving, as he would say, through the front door and not through the back door. The strategy fundamentally hasn't changed. The guidance that we gave earlier in the year around the SEK 55 billion target by 2030 remains. The commitment to the launch has remained. Operationally, everything continues. This is very much a company where our model is that we source external opportunities, we develop them, we get them registered, and we commercialize. The need to do further acquisitions and business development remains as well. In terms of the search, I mean, as management, we're not involved. It's very much handled by the search committee from the board.

As far as I know, and I've heard then, all of that is continuing, and the expectation is to have somebody announced by the end of the year.

Michael Leuchten
Analyst, Jefferies

Got it. Thank you. I guess staying high level for one more then as well, in terms of the portfolio that you have in front of you now, what do you think is perhaps where investors are most underappreciating the longer-term opportunity?

Daniel Rankin
Chief Business Officer, SOBI

I mean, I probably would default to Gerard for what the investors really think. I think, we have this cadence of launches coming out, so we're in the middle of launching Altuviiio. We're launching Aspaveli. We just had the approval for Tryngolza this morning for SHTG, which we're launching. Then we have the two gout programs, which will then, we'll be filing mid-next year and then launching sort of shortly after. I think there's a lot in the execution. The SEK 55 billion we're on track to hit. Could we do more? I think that's a question. Yeah. Anything to add, Gerard?

Gerard Tobin
Head of Investor Relations, SOBI

Yeah. I think just on broadly, I think on consensus, it is the future ones. It is probably pozdeutinurad, the gout franchise in the U.S. is maybe, I would feel a bit underappreciated. Tryngolza, I think people are still getting their heads around the opportunity as it is, I mean, they are both relatively new areas without existing products, so I understand sort of the difficulty, but they are probably the two areas. I think Altuviiio now is pretty well understood in hemophilia.

Daniel Rankin
Chief Business Officer, SOBI

Yeah.

Michael Leuchten
Analyst, Jefferies

If we start there then on Tryngolza, obviously the news this morning of the approval. Do you want to just touch on, was that label exactly what you expected to be post-recommendation? Two, just emphasize the differences between the target profile or the patient profile that the U.S. is focusing on versus Europe and how they differ.

Daniel Rankin
Chief Business Officer, SOBI

I think we are pleased with the label. So it meets our expectations. I think the fundamental difference is that our population is with triglycerides above 880 mg/dL. The U.S. is 550 mg/dL. So that is a fundamental difference.

Michael Leuchten
Analyst, Jefferies

Yeah. In terms of, I guess, we look back to last week and obviously some expectations in the U.S. coming down near a term in terms of the launch. In terms of the setup for lipid centers and the actual commercial reach that you can get within Europe, how does that differ in Europe versus the U.S. in terms of that initial launch and strategy that could occur?

Daniel Rankin
Chief Business Officer, SOBI

I mean, I think you have to remember that we have been in this lipid space for quite a while. So the whole reason why we got Tryngolza was because we had a partnership with Ionis.

Michael Leuchten
Analyst, Jefferies

Yeah.

Daniel Rankin
Chief Business Officer, SOBI

About six years ago, we did that deal. It was a distribution deal. So we have been embedded in the lipid centers. We were already known to the KOLs in the community. We were already in that space. So that is already helping us build those relationships.

Michael Leuchten
Analyst, Jefferies

Yeah.

Daniel Rankin
Chief Business Officer, SOBI

We are now scaling and building a team. We have already had Tryngolza on the market for a short period of time. So they not only knew Waylivra with us, but now they know Tryngolza, and now we are set up with those centers.

Michael Leuchten
Analyst, Jefferies

Yep. That is clear. And in terms of reimbursement cadence, is that something that typically we should assume takes a little bit of a while because it is Europe and cardiovascular? Is that fair?

Daniel Rankin
Chief Business Officer, SOBI

I mean, it's Europe, so we'll follow a standard reimbursement timeline. Germany first and then launch in the other markets and get reimbursement as it comes along.

Michael Leuchten
Analyst, Jefferies

Yeah. Got it.

Gerard Tobin
Head of Investor Relations, SOBI

I think one thing which is, I think helps us as well is that, we mentioned in our label is above 880 mg/dL. So no matter whether you're in the U.S. or Europe, that's seen as the high-risk population. And we have one dose. So our label in a way is a cleaner message and easier to understand.

Michael Leuchten
Analyst, Jefferies

Yeah. I guess in terms of the guidance you've given longer term, if you put that in context, what does that assume in terms of potential competition? Is it taking into account XYZ?

Daniel Rankin
Chief Business Officer, SOBI

I mean, I think if you look at our space, probably there's around a million patients within this. You narrow that down into the severe patients, probably a third of them are severe. Then you kind of look at a reasonable price to get with the competition. I think there's room for both within the guidance that we've given long term.

Michael Leuchten
Analyst, Jefferies

Yeah. Very fair. You mentioned Altuviiio at the start as well, so we probably should touch on it. Very strong performance the last couple of quarters. Where are we in terms of that launch cycle? I think we often talk about three waves. How far progressed are we through those, and what upside is left to come from additional regions or areas?

Daniel Rankin
Chief Business Officer, SOBI

Yeah. So, I mean, the wave one, obviously, Germany first. There's still some incremental growth to come from there. We're now starting wave two, so France, Italy, Spain. There's still a lot more to come, and then the wave three will come on. So there's still, I think there's still more room to grow in each of the services.

Gerard Tobin
Head of Investor Relations, SOBI

Yeah. I mean, we have 32 countries launched at this point. So, it is a handful that is left that we have not launched at all, but there is still a couple that it is there. As Daniel said, the wave two is where we are probably seeing the most growth right now, and that will continue.

Michael Leuchten
Analyst, Jefferies

Yeah, got it. Still more launches going on as well, so Aspaveli, rare kidney diseases. Can you talk a little bit about the feedback that you have got for the first couple of months progressing through that launch? You have noted that you have met that target that you had for the full year early. So what has been able to drive that faster than perhaps initially guided uptake?

Daniel Rankin
Chief Business Officer, SOBI

So, yeah, we hit this. We had guided sort of 400 - 500 patients. I think there is about 2/3 of that, if I am right, that would be on commercial versus non-commercial. We have got strong uptake in Germany. We have had the approval since August in Japan, and I think Spain as well. So, we have been aware of this and shaping this market for a while now, so now we are sort of capitalizing on that.

Gerard Tobin
Head of Investor Relations, SOBI

We have seen some, like with Spain, for instance, with Altuviiio as an example, it took us twice as long to get national reimbursements.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

Spain came really quick, so that's really nice and encouraging to see that they gave us national reimbursement rather fast. We'll see towards the end of the year whether we have another large country or not.

Michael Leuchten
Analyst, Jefferies

In terms of patient addition going into next year, is it fair? How do we think about that build going into 2027 in terms of that launch continuing?

Daniel Rankin
Chief Business Officer, SOBI

Yeah. I think it's continuing that build in Europe, some more launches in Europe, and then we now have a broad international footprint, so we're starting to launch in a number of markets in our international region as well. So that's where the other growth will come from.

Michael Leuchten
Analyst, Jefferies

Yeah. On the PNH side as well, so there's still that going on underlying as well. How is that growth going? Has it had a bit of a halo effect by launching additional indications or anything you noticed?

Daniel Rankin
Chief Business Officer, SOBI

I wouldn't say it's a halo. I mean, most of the growth now is coming from nephrology and will continue to come from nephrology.

Michael Leuchten
Analyst, Jefferies

Yeah.

Daniel Rankin
Chief Business Officer, SOBI

I mean, PNH has become more of a crowded space. There's competition from orals, but it's probably fairly stable.

Michael Leuchten
Analyst, Jefferies

Yeah. Got it. And gout as well. So we're still waiting on a few updates from gout. If we start with the NASP side of things.

Daniel Rankin
Chief Business Officer, SOBI

Yeah.

Michael Leuchten
Analyst, Jefferies

I guess my first question is going to be, is there any updates you can provide us in and around the CMC package, getting that refiled? Any comments you can make around that?

Daniel Rankin
Chief Business Officer, SOBI

We had the Type A meeting. The guidance is, we are on track for mid-next year submission.

Michael Leuchten
Analyst, Jefferies

Yep.

Daniel Rankin
Chief Business Officer, SOBI

Then there would be a six-month approval thereafter. Everything is on track for mid-year.

Michael Leuchten
Analyst, Jefferies

Awesome. In terms of that longer-term opportunity, can you remind us what that looks like and what you are specifically competing with in that chronic gout setting?

Daniel Rankin
Chief Business Officer, SOBI

Yeah. It is competing with Krystexxa, so this is more for very severe chronic refractory gout, so patients who are not responding to that. The value proposition with us is we have the combination with the sirolimus nanoparticles for the immunogenicity, and then it is once monthly. If you look at what Krystexxa is doing, we are late to market, but we are going to take some share of that.

Michael Leuchten
Analyst, Jefferies

Should we be thinking about it as in terms of the patients that are already on Krystexxa are the ones that you are targeting? Because there is quite a large patient pool relative that are not actually on a therapy in that chronic gout setting. Are they a target too, and how can you convert that?

Daniel Rankin
Chief Business Officer, SOBI

Potentially. If you look at the way that, all of these uricases have a high level of immunogenicity, and the way that physicians are dealing with it with Krystexxa is to use methotrexate. There is certainly a patient population that is contraindicated for methotrexate, so with liver issues, if there is alcohol and so on. That is clearly a space to play, and then there is the convenience angle, and then as new patients come up, it is not a chronic therapy.

Michael Leuchten
Analyst, Jefferies

Yeah.

Daniel Rankin
Chief Business Officer, SOBI

This is sort of a one-off treatment over a period of time, so we will be able to capture new patients as well.

Michael Leuchten
Analyst, Jefferies

Yeah. Then if we move on to pozdeutinurad as well, so perhaps by volume, a larger opportunity in terms of patient space. Can you remind us about how you are defining that second-line space? It is a little bit-

Daniel Rankin
Chief Business Officer, SOBI

Yeah. I mean, if you look at the gout algorithm and treatment paradigm, in the U.S., somewhere around, like, they say, 3% of the population at any time over their life will have gout. Out of those patients, first of all, start with allopurinol, then they move to other XOIs like febuxostat. The whole proposition with pozdeutinurad is that you have something that is all of those have issues. They have to be titrated and so on. The whole value proposition with pozdeutinurad is it's a once-daily, safe, efficacious, that lowers serum uric acid. It's going to be second line to those XOIs, but before the uricases. Yeah. In our market research, there's definitely a space for drugs in that in the U.S.

Michael Leuchten
Analyst, Jefferies

You've just presented full phase III data last week on REDUCE-2, so perhaps a few comments around what were the big learnings from that presentation and how the KOL feedback has started to shape early now that that data's out there.

Daniel Rankin
Chief Business Officer, SOBI

Do you want to take that one?

Gerard Tobin
Head of Investor Relations, SOBI

Yeah. I mean, the data, I think one of the new things we showed last week was the amount of the goal of treatment in gout is to get below 6 mg /dL of SUA. But it's also important how many patients you're getting below five and four and three, and that was the data we shared last week. That has sort of implications in terms of the tophi and flare resolution you could see. So we were very happy with that data. Then the other thing we mentioned is that, what's plagued the assets in this class to date has mostly been safety.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

It has been a big issue. When you look at the safety profile of pozdeutinurad, I mean, it is extremely clean. I joke that you could take the name off the safety tables on the presentation and you would not be able to tell which was active drug and which was placebo. I mean, this is something, we looked at a lot in the due diligence on it before we bought the asset, and it has really played out in the phase III study. So that has been, I think, very positive also from KOL feedback was this really clean safety profile.

Michael Leuchten
Analyst, Jefferies

Yeah, that is important, certainly. How do you end up thinking about the potential pricing and payer access side of things for this asset?

Daniel Rankin
Chief Business Officer, SOBI

Yeah, I think what we have guided, but I mean, I think we have sort of said that this is, if you think about the patient population, you think about the value proposition, it is probably something like the JAK inhibitors. I do not think it is-

Gerard Tobin
Head of Investor Relations, SOBI

Yeah, I mean, no, we have not gotten too detailed yet until we get closer to launch.

Daniel Rankin
Chief Business Officer, SOBI

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

But we have some more data still to come.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

We have the second study and then also importantly, the tophi and flare data, and that will all come in Q1.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

So that will get and we're on track. Our goal is to file by mid next year, and that we're fully on track for. So that's the next big, I would say, data release you'll see will be around the Q1 timeframe.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

And then with the filing happening by mid-year.

Michael Leuchten
Analyst, Jefferies

Yeah. Can you remind us why, because I guess you took different disclosure strategies between REDUCE-2 and REDUCE-1. With REDUCE-1, you waited to not unblind the initial data until you get the imaging done. Can you remind us why you decided to make that change?

Daniel Rankin
Chief Business Officer, SOBI

I mean, that was a requirement from the FDA. So they want us to pool the data and look at it all together.

Michael Leuchten
Analyst, Jefferies

Yeah. Makes sense.

Gerard Tobin
Head of Investor Relations, SOBI

Yeah. It's an important note, yeah, that we will pool all these data sets together. So the studies are identical and they're designed to be done this. So the actual data we'll submit in the end will be pooled analysis on everything.

Michael Leuchten
Analyst, Jefferies

Yeah. I guess a couple of competitors have decided to run these studies against active comparators, whereas you've done placebo. Is there much consideration we have to put to that with regards to what payers will respond to, or is it just a They will look at it and see what they say.

Daniel Rankin
Chief Business Officer, SOBI

Not in the U.S. Everything that we've done, really the focus is primarily on the U.S. I think for Europe it would be a different story, but that's not really where we see the biggest opportunity.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

At the end of the day, we're going, positioning after allopurinol. We're not going head-to-head against allopurinol.

Daniel Rankin
Chief Business Officer, SOBI

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

That's an important differentiator as well. This was, the studies were designed and set up with the FDA.

Michael Leuchten
Analyst, Jefferies

Okay. Very fair. I guess there's still lots going on in the established franchise. Doptelet is still growing very well, not just in the U.S. but also in other regions. Can you remind us how that growth differs across each different region as we think about coming up to this potential U.S. loss of exclusivity? It matters for us on an investor side.

Daniel Rankin
Chief Business Officer, SOBI

Do you want to take that?

Gerard Tobin
Head of Investor Relations, SOBI

Yeah. I mean, Doptelet, it has been growing spectacularly well. I mean, even I would say surprising to us considering the Promacta generic, we expected some moderation last year in the U.S., and we have not seen it at all, which really stands to the product. It's still the majority of sales are coming from the U.S. Just the timeline, we will lose exclusivity in July next year, in 2027, in the U.S. only. Europe is 2029 and Japan is 2032, as an example. So we have, ex-U.S., we have much longer protection. Actually, the highest growth right now is in what we call our international region. That has been growing. We've launched only in Japan last year, and that has been a really strong launch. So we'll see where we get to. As I said, the majority is still the U.S. sales.

We'll see where we are by mid next year. What you'll expect next year will be this impact on the second half of the U.S. only sales. As I said, we're still growing ex-U.S. quite well. So overall, I think, when we look at all the launches we have, we don't see this really being, at a group level, it's not going to have an impact. We can absorb this loss. It's actually the only LOE until the sort of the mid-30s that we have actually in the company. So the whole portfolio is quite well protected.

Michael Leuchten
Analyst, Jefferies

That is a very good point. It is not often we find companies that can say that to the mid-2030s.

Gerard Tobin
Head of Investor Relations, SOBI

Yeah.

Michael Leuchten
Analyst, Jefferies

I guess my final one on this is just, have you said how we should be thinking about the speed of generic entry into a market like this, as much you can add.

Gerard Tobin
Head of Investor Relations, SOBI

We still have not seen. They still have time to file.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

We have not seen a lot of activity, but we do not also have good visibility.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

Our base case is there will be generics after July next year. But how many, and the pace, we still don't know.

Michael Leuchten
Analyst, Jefferies

Yeah, that's fine. If we think a little bit more financially now, I know that we've switched the presenters a little bit, but I'm going to touch on there anyway. If we start with the M&A angle, you touched on it at the start, which I thought was interesting. What is the priority for SOBI and its management now? Do we have to wait for a new CEO to come in to make any bigger decisions in and around acquisitions? How should we be thinking from the outside?

Daniel Rankin
Chief Business Officer, SOBI

Yeah. We've had multiple conversations with our board around this in the transition period, and they were very clear that, as I said in the beginning, the overall strategy of the company hasn't changed. It's not a transformation case. This is a CEO that's going on to something different. They're very keen that we don't lose momentum and we continue to do things. We are disciplined around what we are doing. Fundamentally, our strategy sort of follows two components, similar to what we've done over the last years. One would be to look for close-to-market opportunities or on-market opportunities to build scale wherever that makes sense strategically in terms of the fit, and the other is to build a long-term pipeline. So, go earlier than we traditionally have, but specifically building in these franchises.

As we go and we create these potential blockbusters, we're building very good medical teams, we're building very good commercial teams, we're building relationships with physicians, with payers in those therapeutic areas. We want to double down on those. That said, we always have a degree of opportunism. So we won't say no to a good opportunity, if it comes across our desk.

Michael Leuchten
Analyst, Jefferies

Yeah. Have you said much about sizing or firepower at this stage?

Daniel Rankin
Chief Business Officer, SOBI

Let's just say in this interim period, we're not going to do a very, very large deal. We've been relatively disciplined either way. We have very good financial capacity. We've got good debt capacity. There's always the royalty stream that we can monetize if we have to. We have a shareholder who's willing to invest for the right opportunity. We have everything within our realm, but I think, at the moment, it's primarily just within our firepower, within our leverage.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

I think financially, we're in a good position right now. We're about 1.1 x EBITDA.

Daniel Rankin
Chief Business Officer, SOBI

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

We've said before, we can go up to 3x to 4x--

Daniel Rankin
Chief Business Officer, SOBI

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

--we have deleveraged. That is part of the model. We generate a lot of cash, we deleverage quite quickly.

Daniel Rankin
Chief Business Officer, SOBI

Yeah. We delever, and as we grow EBITDA, that just increases our financial capacity as well.

Michael Leuchten
Analyst, Jefferies

Yeah. I guess you touched on that royalty stream as well, and part of the thinking on that deleveraging and where profits go is that Beyfortus royalty stream and how that comes in. How do you have to think about that longer term when you are planning things like this? What are the assumptions that you make in terms of where that product can go and how stable that stream can stay?

Daniel Rankin
Chief Business Officer, SOBI

We actively monitor it. We have our own view on that, as probably many people do when they follow the company. It is going to be a long-term product with cash, so, we just model it like we would anything else, just albeit without the control that we have.

Michael Leuchten
Analyst, Jefferies

Yeah. Is there much you can touch on in terms of what you're seeing within the market now? I know it's not for you to make comments in and around Beyfortus specifically, but we think about the RSV market as a whole, what signs are you seeing in the U.S. in terms of the season?

Daniel Rankin
Chief Business Officer, SOBI

We periodically do market research around this, just to monitor that. We did some research with 100 physicians. All of them will continue to use it. They probably, I think the majority will be using it more than they were previously. We think that the product is in a good shape. There's obviously questions around the inventory and this, that we don't have visibility into. But the demand is certainly there with Beyfortus and isn't diminishing.

Michael Leuchten
Analyst, Jefferies

Yeah. Look, it was reflected in your Q3 results. Again, very strong. Saw another top-line guidance raise. Left the margin unchanged, which I think raised a couple of questions in and around the call. But what were the key uncertainties that you see going into the fourth quarter that made the team as a whole, I realize, from where we sit here, what drove that decision to decide to reiterate that margin aim, and what are the key uncertainties?

Gerard Tobin
Head of Investor Relations, SOBI

Yeah, I think we just touched on one. Beyfortus is always a bit of a swing factor for us in Q3 and Q4, because of this seasonal change, fluctuations we see. We've said it throughout the whole year, our OpEx is ramping up as we get more into the launches. This morning, we got the Tryngolza approved. We're now going to be launching that almost three months earlier than we initially thought. We always knew Q4 from an OpEx perspective would be the heaviest in terms of launches. It was just, it's a window. We went from mid-30 to high 30s. We were 40% year to date, so more than likely we're probably going to be a bit on the higher end. I mean, it's unlikely. But that's kind of the push and pulls.

It is the higher OpEx because we are going into more launches, and this bit deals certainly with Beyfortus seasonality.

Michael Leuchten
Analyst, Jefferies

Yeah. I guess the one thing we then end up looking at is the exit rate and looking into next year. So perhaps you just quickly just touch on it for us in the sense of, what are the levers going into next year we should be aware of, both on a top-line perspective as well as a more of an OpEx basis as well, if I can?

Daniel Rankin
Chief Business Officer, SOBI

I would say obviously the launch of Tryngolza is a key one. Uptake in Aspaveli, in C3G, Altuviiio continuing to grow. Then we have a number of catalysts. There is the positive interim data that will come out in Q1, then there is the filing of NASP, then the filing of positive interim.

Michael Leuchten
Analyst, Jefferies

That is clear. I guess, I like thinking on cost level as well. Is there much we can touch on here?

Gerard Tobin
Head of Investor Relations, SOBI

I mean, it's still a launch year, so it'll be still an investment year next year because we're still early, just starting Tryngolza now. We're only nine months into Aspaveli. We're launching Gamifant in Japan. We've got approval also for Gamifant in Europe next year.

Michael Leuchten
Analyst, Jefferies

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

There's quite a significant amount of launches still to fund going into next year.

Michael Leuchten
Analyst, Jefferies

Yeah. Very clear. I guess with all of that then, we've touched on a lot of things. Is there anything else perhaps you would say that we should have spoken about in this time that obviously we haven't touched on in the Q&A? Broad question. It's always tough to be put on the spot.

Gerard Tobin
Head of Investor Relations, SOBI

No, we're quite excited with the Tryngolza news this morning. This has been incredibly fast to get, not only the CHMP two months ahead of schedule, but the EC decision a month ahead of schedule.

Michael Leuchten
Analyst, Jefferies

Okay.

Daniel Rankin
Chief Business Officer, SOBI

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

This has been very encouraging when you think about from the European perspective. We are really excited to go into that launch. The gout franchise in the U.S. as well, I think is an exciting area for us.

Daniel Rankin
Chief Business Officer, SOBI

Yeah.

Gerard Tobin
Head of Investor Relations, SOBI

We did not talk about it, but Gamifant and sepsis, which I know I get lots of questions on it, that is in early stages. But we are setting up the study. We have a clear plan. We will have some data in 2028. That is progressing quite well. But that is a long-term play. That is going to take time.

Daniel Rankin
Chief Business Officer, SOBI

I would have said IDS, and then the other thing, maybe went a little under the radar, we bought a company, which we closed in October, in Latin America.

Michael Leuchten
Analyst, Jefferies

Yeah.

Daniel Rankin
Chief Business Officer, SOBI

It sort of solidifies now our international footprint. We are now a fully-fledged international pharma company. As we go through those launches where we have the rights, we will be able to launch that in Latin America as well as other markets. That company made about SEK 99 million sales--

Michael Leuchten
Analyst, Jefferies

Yeah.

Daniel Rankin
Chief Business Officer, SOBI

--in the last year.

Michael Leuchten
Analyst, Jefferies

I guess a good summary, there is a lot going on at the moment.

Daniel Rankin
Chief Business Officer, SOBI

Yes.

Michael Leuchten
Analyst, Jefferies

Lots of launches to look forward to next year, and then longer term, still lots to look out to. Look, with that, I want to thank you both very much for your time. Thank you all for coming.